Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to $425 million. Deal will add up to 13 approved products and additional pipeline products.

Current stock price: 2,046.00 pence

12-month change: down 16%

Copyright 2022 Alliance News Limited. All Rights Reserved.